- Home
- SNDA vs MREO Comparison
SNDA vs MREO Comparison
Compare SNDA & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDA
- MREO
- Stock Information
- Founded
- SNDA 1990
- MREO 2015
- Country
- SNDA United States
- MREO United Kingdom
- Employees
- SNDA N/A
- MREO N/A
- Industry
- SNDA Hospital/Nursing Management
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- SNDA Health Care
- MREO Health Care
- Exchange
- SNDA Nasdaq
- MREO Nasdaq
- Market Cap
- SNDA 462.3M
- MREO 482.5M
- IPO Year
- SNDA 1997
- MREO N/A
- Fundamental
- Price
- SNDA $23.79
- MREO $2.51
- Analyst Decision
- SNDA Hold
- MREO Strong Buy
- Analyst Count
- SNDA 1
- MREO 6
- Target Price
- SNDA $25.00
- MREO $7.83
- AVG Volume (30 Days)
- SNDA 29.5K
- MREO 1.5M
- Earning Date
- SNDA 03-17-2025
- MREO 03-26-2025
- Dividend Yield
- SNDA N/A
- MREO N/A
- EPS Growth
- SNDA N/A
- MREO N/A
- EPS
- SNDA N/A
- MREO N/A
- Revenue
- SNDA $253,196,000.00
- MREO $1,000,000.00
- Revenue This Year
- SNDA $14.30
- MREO N/A
- Revenue Next Year
- SNDA $9.72
- MREO N/A
- P/E Ratio
- SNDA N/A
- MREO N/A
- Revenue Growth
- SNDA 10.95
- MREO N/A
- 52 Week Low
- SNDA $18.58
- MREO $2.25
- 52 Week High
- SNDA $34.26
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- SNDA 46.79
- MREO 38.01
- Support Level
- SNDA $23.41
- MREO $2.25
- Resistance Level
- SNDA $25.04
- MREO $2.65
- Average True Range (ATR)
- SNDA 1.24
- MREO 0.17
- MACD
- SNDA -0.15
- MREO 0.01
- Stochastic Oscillator
- SNDA 43.67
- MREO 38.81
About SNDA Sonida Senior Living Inc.
Sonida Senior Living Inc is an owner-operator of senior housing communities in the United States in terms of resident capacity. It provides senior living services to the elderly, including independent living, assisted living, Respite Care and Temporary Care Programs, Home Care Services, and memory care services. The company's objective is to provide value to residents by providing quality senior housing services at reasonable prices. The basic service of the company is comprised of meals, housekeeping, laundry, 24-hour staffing, transportation, social and recreational activities, and healthcare monitoring.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).